Clotting, bleeding issues uncommon with AstraZeneca COVID-19 vaccineThe AstraZeneca-Oxford COVID-19 vaccine is associated with some increases in bleeding and clotting events, according to a BMJ study yesterday, but experts say the benefits outweigh the risks.The researchers compared 28-day post-vaccination comorbidities in 291,264 Danish and Norwegian adults under 65 with the general population.
Most (79.0%) were women, with a median age for all patients of 44 to 45. People who had experienced any adverse events in the past year were excluded.The results show no association between arterial events and COVID vaccination, but the risk of venous thromboembolism was increased 1.97-fold, though to only 11 excess occurrences per 100,000